

BIODOL Therapeutics and KYORIN Pharmaceutical announce strategic Option Agreement for license to BDT272, a first-in-class treatment for pain

Montarnaud, France, 14 January 2025, 9AM CET Time – BIODOL Therapeutics (“Biodol”), a company dedicated to discovering innovative pain treatments targeting FLT3, announced today that it has entered into an option agreement with KYORIN Pharmaceutical (“Kyorin”), a major Japanese pharmaceutical company focusing on the discovery and development of therapies for diseases with significant unmet need. Pain has recently been identified as a strategic focus area for Kyorin, and the two companies share a common vision regarding the potential of the FLT3 target.

Under the terms of the agreement, Biodol will receive an option fee, granting Kyorin the option to in-license BDT272 upon the successful completion of Phase 1 clinical trials. Upon exercise of the option, Kyorin will be granted a license to develop and commercialize the compound in Japan and selected additional territories in Asia (excluding China); in turn Biodol will receive upfront payment, milestone payments tied to the progress of developing and commercializing BDT272, and royalties based on net sales following its launch.

“We are proud to collaborate with Kyorin, a trusted and well-established partner with deep market expertise and a proven track record in bringing therapies to patients. This agreement is a key milestone for Biodol, as we join forces to deliver innovative pain treatments to address significant unmet medical needs.” said Fabien GRANIER, CEO of BIODOL Therapeutics.

“Our company is focused on pain as one of our key strategic therapeutic areas for research and development. Through this agreement, we anticipate that this innovative pain treatment candidate will provide a new treatment option for patients suffering from pain conditions.” said Yutaka Ogihara, President and CEO of KYORIN Pharmaceutical Co., Ltd.

About Kyorin Pharmaceutical

KYORIN Pharmaceutical Co., Ltd. was founded in 1923. Accelerating its evaluation and acquisition of in-licensed products and establishing a presence in designated fields, Kyorin aims to contribute broadly to people’s health by pursuing innovation in drug discovery, in order to strengthen drug discovery capability and create high-value new drugs that meet medical needs.

About Biodol Therapeutics

Biodol Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its

groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). Biodol Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various types of pain. The company holds exclusive rights to a portfolio of four patents and has received support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre. Biodol was assisted by MCE Carrel law firm, Alexandra Carrel and Luke Sampson, for this transaction.

For more information, please contact:

Biodol Therapeutics

contact@biodol.eu